Saturday 10 October 2026

One To Watch

UTILITY Therapeutics

A biotech company developing Pivmecillinam for the treatment of urinary tract infections (UTI).

Company Overview

Want to Update your Company's Profile?


More UTILITY Therapeutics news >


Today's issue

Mineralys presents new data for lorundrostat
Pharmaceutical
Mineralys presents new data for lorundrostat
9 October 2026
Pharmaceutical
Colombian pharma groups sign alliance to fight counterfeit medicines
9 October 2026
Biotechnology
Outlook Therapeutics appoints Greg DiPasquale as CCO
9 October 2026
Biotechnology
Lonza and Onava collaborate to speed AI-native biologics discovery
9 October 2026
Pharmaceutical
FDA approves Teva’s Weltruza for schizophrenia
9 October 2026
Pharmaceutical
Foundayo potential as differentiated oral option for weight and glycemic control
9 October 2026
Generics
India's pharma industry looks beyond USA as trade uncertainty grows
9 October 2026




Copyright © The Pharma Letter 2026

 |  Headless Content Management with Blaze